Stock AnalizDamora Therapeutics, Inc. DMRA
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Damora Therapeutics, Inc. (DMRA) is a healthcare company listed in the US with a market value of about $1.3B.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 13.3, a 5-year average ROIC of -89%.
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$210M | -$21M | -$38M | -$62M | -$52M | -$35M | -$37M |
| Free cash flow | — | — | — | -$43M | -$53M | — | — |
| EPS (diluted) | $3.98 | $-18.53 | $-36.08 | $-60.75 | $-51.25 | $-190.50 | $-4045.49 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | -69.3% | -110.6% | -122.5% | -97.8% | -44.2% | -20.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $46.78, 117% above the current price; targets range from $40.00 to $59.00; the consensus rating is “Strong buy”; expected EPS is $-1.89 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Damora Therapeutics’s P/E ratio?
About 13.3, based on the last twelve months of diluted earnings per share.
Does Damora Therapeutics pay a dividend?
Not currently.
Is Damora Therapeutics a good stock to buy?
We do not give buy or sell advice. Damora Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.